Holen Sie sich die Stockscreener-App
6.16
5.38%
-0.35
Schlusskurs vom Vortag:
$6.51
Offen:
$6.45
24-Stunden-Volumen:
76,495
Relative Volume:
0.58
Marktkapitalisierung:
$156.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-4.3688
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-7.78%
1M Leistung:
-9.68%
6M Leistung:
-20.41%
1J Leistung:
-5.23%
1-Tages-Spanne:
$6.15
$6.4661
1-Wochen-Bereich:
$6.15
$6.88
52-Wochen-Spanne:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.16 | 159.87M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Full technical analysis of Nuvectis Pharma Inc. stockExit Point & AI Powered Buy/Sell Recommendations - Newser
Custom watchlist performance reports with Nuvectis Pharma Inc.July 2025 Market Mood & Scalable Portfolio Growth Ideas - Newser
How high can Nuvectis Pharma Inc. stock goJuly 2025 Macro Moves & Capital Protection Trading Alerts - Newser
Best data tools to analyze Nuvectis Pharma Inc. stockQuarterly Earnings Summary & Community Consensus Stock Picks - Newser
Smart tools for monitoring Nuvectis Pharma Inc.’s price actionJuly 2025 Movers & Smart Allocation Stock Reports - Newser
Should you wait for a breakout in Nuvectis Pharma Inc.2025 Pullback Review & Fast Entry High Yield Stock Tips - Newser
Why Nuvectis Pharma Inc. is moving todayMarket Sentiment Report & Real-Time Volume Analysis - Newser
Nuvectis Pharma Inc.’s volatility index tracking explainedWeekly Profit Analysis & Weekly High Return Forecasts - Newser
Will breakout in Nuvectis Pharma Inc. lead to full recoveryEarnings Beat & Technical Buy Zone Confirmation - Newser
How to escape a deep drawdown in Nuvectis Pharma Inc.2025 Short Interest & Community Trade Idea Sharing - Newser
What to expect from Nuvectis Pharma Inc. in the next 30 days2025 Trade Ideas & High Conviction Investment Ideas - Newser
Can technical indicators confirm Nuvectis Pharma Inc.’s reversalMarket Weekly Review & Verified Swing Trading Watchlist - Newser
How to recover losses in Nuvectis Pharma Inc. stock2025 Price Action Summary & AI Based Trade Execution Alerts - Newser
Nuvectis Pharma Inc. stock trend outlook and recovery pathMarket Trend Report & Safe Capital Growth Tips - Newser
Combining machine learning predictions for Nuvectis Pharma Inc.Weekly Profit Recap & Verified Momentum Watchlists - Newser
Is Nuvectis Pharma Inc. stock ready for a breakoutEarnings Summary Report & Detailed Earnings Play Alerts - Newser
What recovery options are there for Nuvectis Pharma Inc.Quarterly Performance Summary & Expert-Curated Trade Recommendations - Newser
Tools to monitor Nuvectis Pharma Inc. recovery probability2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser
Analyzing Nuvectis Pharma Inc. with multi timeframe chartsEarnings Trend Report & Verified Entry Point Signals - Newser
Nuvectis Pharma Inc. stock chart pattern explainedPortfolio Value Summary & Weekly Watchlist of Top Performers - Newser
What earnings revisions data tells us about Nuvectis Pharma Inc.Quarterly Investment Review & Reliable Breakout Forecasts - Newser
Nuvectis Pharma Inc. recovery potential after sell off2025 Earnings Surprises & Safe Swing Trade Setup Alerts - Newser
Using AI based signals to follow Nuvectis Pharma Inc.Weekly Investment Summary & AI Powered Trade Plan Recommendations - Newser
Is Nuvectis Pharma Inc. still worth holding after the dipJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
What Fibonacci levels say about Nuvectis Pharma Inc. reboundPortfolio Performance Report & Weekly Breakout Stock Alerts - Newser
What MACD signals say about Nuvectis Pharma Inc.Trend Reversal & Daily Momentum Trading Reports - Newser
Is Nuvectis Pharma Inc. stock entering bullish territoryMarket Growth Review & Low Drawdown Investment Ideas - Newser
Price action breakdown for Nuvectis Pharma Inc.Market Activity Summary & Consistent Profit Focused Trading Strategies - Newser
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Earnings Growth Summary & Daily Technical Forecast Reports - Newser
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):